Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system

被引:62
作者
Setsuta, K
Seino, Y
Ogawa, T
Ohtsuka, T
Seimiya, K
Takano, T
机构
[1] Nippon Med Coll, Dept Med 1, Bunkyo Ku, Tokyo 1138603, Japan
[2] Hakujikai Mem Gen Hosp, Dept Med, Div Cardiol, Tokyo, Japan
[3] Tokyo Metropolitan Komagome Hosp, Dept Med, Div Cardiol, Tokyo, Japan
关键词
apoptosis; Fas/Fas ligand; fatty acid-binding protein; heart failure; tumor necrosis factor;
D O I
10.1253/circj.68.747
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Elevated concentrations of cardiac troponin T and heart-type fatty acid-binding protein (H-FABP) identify patients with chronic heart failure (CHF) and ongoing myocardial damage (OMD) who are at increased risk for future cardiac events. Cardiomyocyte necrosis and/or apoptosis via activated tumor necrosis factor (TNF) and the Fas/Fas ligand (FasL) system may be related to the development of OMD. Methods and Results The serum concentrations of H-FABP, a sensitive marker of membrane damage of cardiomyocytes, soluble Fas (sFas) and TNF-alpha were measured in 38 patients with CHF. The concentrations of H-FABP, TNF-alpha and s-Fas in patients with New York Heart Association (NYHA) III + IV were all significantly higher than in those patients in NYHA II (H-FABP; III + IV 9.3+/-5.9 vs II 5.1+/-1.8 ng/ml, p=0.003, TNF-alpha; III + IV 10.5+/-3.8 vs II 8.0+/-2.7pg/ml, p=0.02, sFas; III + IV 3.36+/-1.37 vs II 2.58+/-0.84 ng/ml, p=0.03). Increased concentrations of H-FABP significantly correlated with the concentrations of TNF-alpha (r=0.57, p=0.0001) and sFas (r=0.69, p<0.0001), independent of renal function. Conclusion OMD detected by H-FABP, a marker of membrane damage, is related to activated TNF and the Fas/FasL system, which suggests a pathophysiological role of cardiomyocyte necrosis and/or apoptosis in patients with worsening heart failure.
引用
收藏
页码:747 / 750
页数:4
相关论文
共 25 条
[1]   Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure [J].
Bozkurt, B ;
Torre-Amione, G ;
Warren, MS ;
Whitmore, J ;
Soran, OZ ;
Feldman, AM ;
Mann, DL .
CIRCULATION, 2001, 103 (08) :1044-1047
[2]  
CASCINO I, 1995, J IMMUNOL, V154, P2706
[3]   PROTECTION FROM FAS-MEDIATED APOPTOSIS BY A SOLUBLE FORM OF THE FAS MOLECULE [J].
CHENG, JH ;
ZHOU, T ;
LIU, CD ;
SHAPIRO, JP ;
BRAUER, MJ ;
KIEFER, MC ;
BARR, PJ ;
MOUNTZ, JD .
SCIENCE, 1994, 263 (5154) :1759-1762
[4]   Expression of FAS adjacent to fibrotic foci in the failing human heart is not associated with increased apoptosis [J].
Filippatos, G ;
Leche, C ;
Sunga, R ;
Tsoukas, A ;
Anthopoulos, P ;
Joshi, I ;
Bifero, A ;
Pick, R ;
Uhal, BD .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 277 (02) :H445-H451
[5]  
Gorski J, 1997, CLIN CHEM, V43, P193
[6]   Myocyte death in the failing human heart is gender dependent [J].
Guerra, S ;
Leri, A ;
Wang, XW ;
Finato, N ;
Di Loreto, C ;
Beltrami, CA ;
Kajstura, J ;
Anversa, P .
CIRCULATION RESEARCH, 1999, 85 (09) :856-866
[7]   Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure [J].
Horwich, TB ;
Patel, J ;
MacLellan, WR ;
Fonarow, GC .
CIRCULATION, 2003, 108 (07) :833-838
[8]   Serum levels of soluble Fas antigen in chronic hepatitis C patients [J].
Iio, S ;
Hayashi, N ;
Mita, E ;
Ueda, K ;
Mochizuki, K ;
Hiramatsu, N ;
Kanto, T ;
Sasaki, Y ;
Kasahara, A ;
Hori, M .
JOURNAL OF HEPATOLOGY, 1998, 29 (04) :517-523
[9]   THE POLYPEPTIDE ENCODED BY THE CDNA FOR HUMAN CELL-SURFACE ANTIGEN FAS CAN MEDIATE APOPTOSIS [J].
ITOH, N ;
YONEHARA, S ;
ISHII, A ;
YONEHARA, M ;
MIZUSHIMA, S ;
SAMESHIMA, M ;
HASE, A ;
SETO, Y ;
NAGATA, S .
CELL, 1991, 66 (02) :233-243
[10]   CYTOTOXIC MECHANISM OF TUMOR-NECROSIS-FACTOR-ALPHA [J].
LARRICK, JW ;
WRIGHT, SC .
FASEB JOURNAL, 1990, 4 (14) :3215-3223